Anika Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Anika Therapeutics is a global orthopedic medicines company focused on hyaluronic acid technologies and products including ORTHOVISC, MONOVISC, CINGAL, HYALOFAST, and wound-care products. The filing covers the three and nine months ended September 30, 2016; financial statements are unaudited.
Financial Performance and Position
| Metric | Q3 2016 | Q3 2015 | 9M 2016 | 9M 2015 |
|---|---|---|---|---|
| Total revenue | $25.8 million | $23.7 million | $74.7 million | $62.1 million |
| Product revenue | $25.8 million | $23.7 million | $74.6 million | $62.1 million |
| Income from operations | $13.7 million | $13.1 million | $37.9 million | $31.1 million |
| Net income | $9.0 million | $8.4 million | $24.5 million | $19.7 million |
| Diluted EPS | $0.59 | $0.55 | $1.61 | $1.29 |
| Operating cash flow | Not separately reported | Not separately reported | $18.0 million | $23.8 million |
- Q3 revenue increased 9%; nine-month revenue increased 20%. Net income increased 7% in Q3 and 24% for the nine-month period.
- Product gross profit was $20.8 million in Q3 and $58.1 million for nine months. Product gross margin was 81% and 78%, respectively, compared with 78% and 76% in the prior-year periods.
- Q3 operating margin was approximately 53%; nine-month operating margin was approximately 51%. Q3 net margin was approximately 35%; nine-month net margin was approximately 33%.
- Research and development expense increased 37% in Q3 and 30% for nine months, principally from HYALOFAST clinical activity and other development programs. SG&A increased 29% and 22%, respectively.
- Cash, cash equivalents, and investments totaled $120.3 million at September 30, 2016, versus $138.5 million at December 31, 2015. Working capital was approximately $153.5 million.
- Cash and cash equivalents were $98.0 million, compared with $110.7 million at year-end 2015. Investments were $22.3 million.
- The filing does not identify outstanding debt or borrowings; reported liabilities were $16.5 million, including $7.6 million of current liabilities and $2.6 million of other long-term liabilities.
Material Changes Versus the Prior Comparable Period
- Orthobiologics revenue increased 10% in Q3 and 26% for nine months, driven primarily by higher U.S. MONOVISC revenue and increased ORTHOVISC and MONOVISC volumes.
- International orthobiologics revenue increased 27% for the nine-month period. Pricing concessions by the U.S. commercial partner partially offset volume gains.
- Surgical revenue declined 17% in Q3 and 12% for nine months, primarily because of lower sales to the worldwide ENT commercial partner.
- Dermal revenue increased 44% in Q3 and 38% for nine months, reflecting demand growth and distributor order timing.
- Operating cash flow declined $5.8 million year over year, primarily because of planned inventory buildup, lower accounts payable and income taxes payable.
- Capital expenditures increased substantially, with $12.6 million spent on property and equipment through nine months versus $2.0 million in the prior-year period.
- The company completed a $25.0 million accelerated share repurchase, receiving 531,067 shares at an average repurchase price of $47.08. Outstanding shares declined to approximately 14.6 million from 15.0 million at year-end 2015.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected orthobiologics revenue to continue growing through year-end 2016, supported by MONOVISC, CINGAL availability in Canada and Europe, and broader viscosupplementation demand.
- Management expected surgical revenue to decline moderately, other product revenue to decline, and dermal revenue to increase for full-year 2016.
- R&D and SG&A expenses were expected to increase in 2016 and beyond as the company expands clinical, commercial, and product-development activities.
- CINGAL launched in Canada in May 2016 and the European Union in June 2016. Following September 2016 discussions with the FDA, the company expected to submit an IND and begin an additional Phase III trial by early 2017, subject to finalizing requirements.
- The company expected to spend approximately $25 million on transferring HYAFF-based manufacturing from Italy to Bedford, Massachusetts. It spent approximately $0.9 million on the project during Q3 and expected to spend an additional $4.2 million over the following nine months.
- A new European headquarters and manufacturing-related facility in Padova, Italy was under construction, with expected lease commencement in the first quarter of 2017. The facility lease has an initial 15-year term and initial annual rent of approximately $0.4 million.
- Management stated that available cash, investments, and operating cash flow were adequate to support the business for at least the next twelve months.
- Key risks include competition, supply interruptions, product quality issues, pricing pressure, regulatory approvals, healthcare policy changes, international operations, intellectual-property protection, and dependence on commercial partners. No material changes to previously disclosed risk factors were reported.
- The company reported ordinary-course legal proceedings and ongoing U.S. and Italian tax audits, but did not expect either to have a material adverse effect. No accrued product warranties were recorded.
Important Facts for Investors to Verify
- Confirm the sustainability of MONOVISC-driven orthobiologics growth and the effect of partner pricing concessions.
- Track CINGAL’s commercial performance in Canada and Europe and the timing, cost, and regulatory requirements of the additional U.S. Phase III program.
- Assess whether the Bedford manufacturing transfer remains within the approximately $25 million expected investment and achieves anticipated efficiency benefits.
- Monitor inventory growth, capital expenditures, and the decline in operating cash flow.
- Review the absence of reported borrowings alongside the company’s cash and investment balances, and assess future funding needs for clinical development and manufacturing expansion.
- Evaluate execution risks related to regulatory approvals, clinical-trial enrollment, international operations, distributors, and commercial partners.